BioSpace News Archive

MorphoSys AG and I-Mab Biopharma announced that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.

The U.S. Department of Health and Human Services Office of the Chief Technology Officer and the American Society of Nephrology have selected 15 winning teams for Phase 1 of the KidneyX Redesign Dialysis prize competition.

Motif Bio plc announced the appointment of Andrew Powell, J.D. as Non-executive Director, effective immediately.

Motif Bio plc announced that its notice of its Annual General Meeting have been posted to shareholders and will shortly be available for download from the Company’s website at www.motifbio.com.

Novo Nordisk announced positive results from its ELLIPSE Phase III clinical trial of Victoza (liraglutide) in treating type 2 diabetes in children aged 10 to 17. The company presented the results at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting held in Baltimore, MD, and simultaneously published in the New England Journal of Medicine.

Calixar is providing Regeneron exclusive rights to its technology and expertise. Regeneron plans to work on developing antibodies against an undisclosed target in several different therapeutic areas.

Recently, researchers with the Institute of Life in Athens, Greece, announced that a healthy baby boy was born who basically had the DNA from three people. The child was born to a 32-year-old woman who had failed in four cycles of in vitro fertilization (IVF).

Polarean Imaging plc announces the appointment of Charles Osborne, Jr as Chief Financial Officer with immediate effect.

Karolinska Development AB announces that The Board of Directors has decided to delay the publication of its Annual Report for 2018.

Ireland-based Horizon Pharma reported additional statistically significant secondary data from its positive Phase III study at a conference and plans to continue to share analysis at future medical conferences.